(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/123432 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/18* (2017.01)
A61K 9/06 (2006.01) *A61K 47/26* (2006.01)
A61K 47/02 (2006.01) *A61K 38/00* (2006.01)
A61K 47/14 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2020/087461

(22) International Filing Date:
21 December 2020 (21.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

19219008.0	20 December 2019 (20.12.2019)	EP
20186428.7	17 July 2020 (17.07.2020)	EP
20194928.6	07 September 2020 (07.09.2020)	EP

(71) Applicants: **ARES TRADING S.A.** [CH/CH]; Zone Industrielle de L'Ouriettaz, 1170 Aubonne (CH). **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LTD.** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) Inventors: **IORIO, Chiara**; c/o Merck Serono S.p.A. Via Luigi Einaudi 11, 00012 Guidonia Montecelio RM (IT). **PERGOLA, Carlo**; c/o Merck Serono S.p.A. Via Luigi Einaudi 11, 00012 Guidonia Montecelio RM (IT). **CANAL, Fabiana**; c/o Merck Serono S.p.A. Via Luigi Einaudi 11, 00012 Guidonia Montecelio RM (IT). **RINALDI, Gianluca**; c/o Merck Serono S.p.A. Via Luigi Einaudi 11, 00012 Guidonia Montecelio RM (IT). **GRIESER, Katrin**; c/o Merck Healthcare KGaA Frankfurter Strasse 250, 64293 Darmstadt (DE). **WEIGANDT, Markus**; c/o Merck Healthcare KGaA Frankfurter Strasse 250, 64293 Darmstadt (DE). **WINZER, Matthias**; c/o Merck Healthcare KGaA Frankfurter Strasse 250, 64293 Darmstadt (DE).

(74) Agent: **MERCK SERONO S.A.**; Terre Bonne Business Park - Building Z0 Route de Crassier 1, 1262 Eysins (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2021/123432 A1

(54) Title: IGG:TGFBETARII FUSION PROTEIN COMPOSITION

(57) Abstract: The present invention relates to a pharmaceutical composition, particularly a pharmaceutical composition comprising an IgG:TGFβRII (such as an anti-PD-L1:TGFβ-inhibiting) fusion protein. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments.